GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Intra-Cellular Therapies Inc (NAS:ITCI) » Definitions » Price-to-Owner-Earnings

Intra-Cellular Therapies (Intra-Cellular Therapies) Price-to-Owner-Earnings : (As of May. 05, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Intra-Cellular Therapies Price-to-Owner-Earnings?

As of today (2024-05-05), Intra-Cellular Therapies's share price is $68.80. Intra-Cellular Therapies does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Intra-Cellular Therapies's Price-to-Owner-Earnings or its related term are showing as below:


ITCI's Price-to-Owner-Earnings is not ranked *
in the Drug Manufacturers industry.
Industry Median: 28.05
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-05-05), Intra-Cellular Therapies's share price is $68.80. Intra-Cellular Therapies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.46. Therefore, Intra-Cellular Therapies's PE Ratio for today is At Loss.

As of today (2024-05-05), Intra-Cellular Therapies's share price is $68.80. Intra-Cellular Therapies's EPS without NRI for the trailing twelve months (TTM) ended in was $-1.46. Therefore, Intra-Cellular Therapies's PE Ratio without NRI for today is At Loss.


Intra-Cellular Therapies Price-to-Owner-Earnings Historical Data

The historical data trend for Intra-Cellular Therapies's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intra-Cellular Therapies Price-to-Owner-Earnings Chart

Intra-Cellular Therapies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Intra-Cellular Therapies Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Intra-Cellular Therapies's Price-to-Owner-Earnings

For the Drug Manufacturers - Specialty & Generic subindustry, Intra-Cellular Therapies's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Intra-Cellular Therapies's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Intra-Cellular Therapies's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Intra-Cellular Therapies's Price-to-Owner-Earnings falls into.



Intra-Cellular Therapies Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Intra-Cellular Therapies's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=68.80/-1.76
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Intra-Cellular Therapies  (NAS:ITCI) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Intra-Cellular Therapies Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Intra-Cellular Therapies's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Intra-Cellular Therapies (Intra-Cellular Therapies) Business Description

Traded in Other Exchanges
Address
430 East 29th Street, New York, NY, USA, 10016
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.
Executives
Sharon Mates director, officer: Chairman, President & CEO C/O INTRA-CELLULAR THERAPIES, INC., 3960 BROADWAY, NEW YORK NY 10032
Michael Halstead officer: SVP and General Counsel C/O WARNER CHILCOTT CORPORATION, 100 ENTERPRISE DRIVE, ROCKAWAY NJ 07866
Suresh K. Durgam officer: Chief Medical Officer C/O INTER-CELLULAR THERAPIES, INC., 430 EAST 29TH STREET, NEW YORK NY 10016
Mark Neumann officer: EVP, Chief Commercial Officer C/O INTRA-CELLULAR THERAPIES, INC., 430 EAST 29TH STREET, NEW YORK NY 10016
Lawrence J. Hineline officer: VP of Finance, CFO & Secretary C/O INTRA-CELLULAR THERAPIES, INC., 3960 BROADWAY, NEW YORK NY 10032
Van Nostrand Robert L director C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511
Joel S Marcus director C/O ALEXANDRIA REAL ESTATE EQUITIES, INC, 26 NORTH EUCLID AVENUE, PASADENA CA 91101
Eduardo Rene Salas director C/O INTRA-CELLULAR THERAPIES, INC., 430 EAST 29TH STREET, NEW YORK NY 10016
Rory B Riggs director 65 RAILROAD AVE, RIDGEFIELD NJ 07657
Christopher D Alafi director, 10 percent owner P.O. BOX 7338, BERKELEY CA 94707
Richard A Lerner director THE SCRIPPS RESEARCH INSTITUTE, 10550 N. TORREY PINES ROAD, LA JOLLA CA 92037
Andrew Satlin officer: EVP and Chief Medical Officer C/O INTRA-CELLULAR THERAPIES, INC., 430 EAST 29TH STREET, NEW YORK NY 10016
Kimberly E. Vanover officer: VP, Clinical Development C/O INTRA-CELLULAR THERAPIES, INC., 3960 BROADWAY, NEW YORK NY 10032
Robert E Davis officer: SVP, Chief Scientific Officer 3911 SORRENTO VALLEY BOULEVARD, SAN DIEGO CA 92121
Moshe Alafi 10 percent owner 1311 ORLEANS DRIVE, SUNNYVALE CA 94089